Biohaven Ltd (BHVN)

$15.00 +0.28 (1.90%)
Market Cap 2.22B
Revenue (ttm) 0.00
Net Income (ttm) -738.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 21.23
Volume 2,817,100
Avg Vol 2,574,236
Day's Range N/A - N/A
Shares Out 151.04M
Stochastic %K 25%
Beta 1.28
Analysts Strong Sell
Price Target $21.27

Company Profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinica...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 404 0410
Address:
215 Church Street, New Haven, United States
MakerQuants
MakerQuants Sep. 9 at 4:05 PM
$BHVN 😲
0 · Reply
anachartanalyst
anachartanalyst Sep. 8 at 6:02 PM
$BHVN https://anachart.com/wp-content/uploads/2026/09/1788890498_soc-img.jpg
0 · Reply
Timefortendies77
Timefortendies77 Sep. 8 at 1:59 PM
$BHVN Someone wanted to buy more.
0 · Reply
Timefortendies77
Timefortendies77 Sep. 8 at 1:31 PM
$BHVN Wow ok 5% down, looks like shorties came to play today.
0 · Reply
Timefortendies77
Timefortendies77 Sep. 7 at 3:44 PM
$BHVN The Path to Becoming the New King-------Efficacy: Prior data on taldefgrobep (from its original testing in spinal muscular atrophy) showed it could drive over a 6% reduction in fat mass while simultaneously increasing lean muscle mass. If those numbers translate cleanly to an obesity cohort as a standalone treatment, it proves the mechanism is an absolute powerhouse. The Side Effect Advantage: The real crown will be won on tolerability. Lilly's bimagrumab has faced hurdles with severe muscle spasms and diarrhea because it binds rigidly to the receptor. If Biohaven’s "ligand trap" approach successfully cleans up the target proteins before they hit the receptor—yielding great body composition with a clean safety profile—it removes the single biggest barrier to widespread adoption.
0 · Reply
Timefortendies77
Timefortendies77 Sep. 7 at 3:13 PM
$BHVN Success in Obesity could be game changing for Biohaven and make the pop for the Epilepsy KV7 drug sale look like pennies compared to what the stock could do here. No Analyst is pricing it in success with obesity----they do not want to be wrong. That means anything that happens is NOT priced in. If it doesn't hit the stock will def take a hit--maybe back down to the 10-12 zone (but of course not to the ground as there are many assets here). It seems the Analysts talk the most about Degraders as they are going into P3 and are more proven than Obesity. Summary-Obesity is a total wild card.
0 · Reply
Timefortendies77
Timefortendies77 Sep. 3 at 9:46 PM
$BHVN Obesity=October
0 · Reply
MonkeyBananaGenius
MonkeyBananaGenius Sep. 3 at 12:33 PM
$BHVN very interesting back story on this one. Precommercial but robust pipeline. Chart looks constructive.
1 · Reply
Valueforall
Valueforall Sep. 2 at 6:33 PM
$BHVN I went against my rule and went 2.5x overweight in dis muddhphukka!
0 · Reply
Dheeraj_6
Dheeraj_6 Sep. 2 at 2:27 PM
$BHVN MM trying hard to manipulate the SP,from +6% on opening to -1% in an hour on such a low volume. I am hopeful we hit Obesity this year, with that this will soar to minimum to $25.
0 · Reply
Latest News on BHVN
Biohaven downgraded to Sector Perform from Outperform at RBC Capital

2026-09-08T09:25:05.000Z - 2 days ago

Biohaven downgraded to Sector Perform from Outperform at RBC Capital

H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’

2026-08-26T17:50:17.000Z - 14 days ago

H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’

XENE

Biohaven rises 10.8%

2026-08-26T16:05:38.000Z - 14 days ago

Biohaven rises 10.8%

Biohaven price target lowered to $30 from $50 at Raymond James

2026-08-26T14:20:09.000Z - 14 days ago

Biohaven price target lowered to $30 from $50 at Raymond James

Biohaven to receive $400M in SK Biopharmaceuticals licensing, collaboration pact

2026-08-26T09:30:25.000Z - 15 days ago

Biohaven to receive $400M in SK Biopharmaceuticals licensing, collaboration pact

Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million

Aug 26, 2026, 2:56 AM EDT - 15 days ago

Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Aug 26, 2026, 2:36 AM EDT - 15 days ago

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University

Aug 25, 2026, 4:41 PM EDT - 15 days ago

Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University

Biohaven price target raised to $19 from $18 at Morgan Stanley

2026-08-17T09:46:38.000Z - 24 days ago

Biohaven price target raised to $19 from $18 at Morgan Stanley

Biohaven price target raised to $23 from $22 at RBC Capital

2026-08-11T13:36:03.000Z - 4 weeks ago

Biohaven price target raised to $23 from $22 at RBC Capital

Biohaven reports Q2 EPS (78c), consensus (61c)

2026-08-10T20:05:24.000Z - 4 weeks ago

Biohaven reports Q2 EPS (78c), consensus (61c)

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results

Aug 10, 2026, 4:02 PM EDT - 4 weeks ago

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results

Biohaven Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

Biohaven Quarterly report: Q2 2026

Biohaven Earnings release: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

Biohaven Earnings release: Q2 2026

Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors

Biohaven and Yale University awarded $4M in trade secret verdict

2026-07-27T11:11:53.000Z - 6 weeks ago

Biohaven and Yale University awarded $4M in trade secret verdict

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

Jul 27, 2026, 7:00 AM EDT - 6 weeks ago

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

Biohaven reports new data on BHV-1530

2026-07-20T11:35:41.000Z - 7 weeks ago

Biohaven reports new data on BHV-1530

Biohaven enters into clinical supply agreement with Regeneron

2026-07-20T11:35:36.000Z - 7 weeks ago

Biohaven enters into clinical supply agreement with Regeneron

REGN

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Jul 20, 2026, 7:30 AM EDT - 7 weeks ago

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Biohaven’s Bruce Car retires as chief scientific officer

2026-07-09T21:05:16.000Z - 2 months ago

Biohaven’s Bruce Car retires as chief scientific officer

Biohaven Announces Scientific Leadership Transitions

Jul 9, 2026, 5:00 PM EDT - 2 months ago

Biohaven Announces Scientific Leadership Transitions

Biohaven announces completion of enrollment in RISE3 trial

2026-06-30T11:35:53.000Z - 2 months ago

Biohaven announces completion of enrollment in RISE3 trial

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Jun 30, 2026, 7:30 AM EDT - 2 months ago

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Biohaven falls -9.8%

2026-06-29T14:05:29.000Z - 2 months ago

Biohaven falls -9.8%

Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease

2026-06-29T11:35:56.000Z - 2 months ago

Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

Jun 29, 2026, 7:30 AM EDT - 2 months ago

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

Biohaven downgraded to Underperform from Neutral at BofA

2026-06-29T10:20:18.000Z - 2 months ago

Biohaven downgraded to Underperform from Neutral at BofA

XENE

Biohaven rises 7.4%

2026-06-26T14:07:04.000Z - 2 months ago

Biohaven rises 7.4%

Biohaven price target raised to $20 from $15 at Deutsche Bank

2026-06-26T12:35:29.000Z - 2 months ago

Biohaven price target raised to $20 from $15 at Deutsche Bank

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

Jun 1, 2026, 7:30 AM EDT - 3 months ago

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

May 27, 2026, 7:30 AM EDT - 3 months ago

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

May 26, 2026, 7:30 AM EDT - 3 months ago

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

May 4, 2026, 4:02 PM EDT - 4 months ago

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven Quarterly report: Q1 2026

May 4, 2026, 4:00 PM EDT - 4 months ago

Biohaven Quarterly report: Q1 2026

Biohaven Earnings release: Q1 2026

May 4, 2026, 4:00 PM EDT - 4 months ago

Biohaven Earnings release: Q1 2026

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Mar 19, 2026, 7:30 AM EDT - 5 months ago

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 6 months ago

Biohaven Proxy statement: Proxy Filing

Biohaven Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 6 months ago

Biohaven Proxy statement: Proxy Filing

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 4:05 PM EST - 6 months ago

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Annual report: Q4 2025

Mar 2, 2026, 4:00 PM EST - 6 months ago

Biohaven Annual report: Q4 2025

Biohaven Earnings release: Q4 2025

Mar 2, 2026, 4:00 PM EST - 6 months ago

Biohaven Earnings release: Q4 2025

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 8 months ago

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Biohaven Slides: 44th Annual J.P. Morgan Healthcare Conference presentation

Jan 12, 2026, 7:00 AM EST - 8 months ago

Biohaven Slides: 44th Annual J.P. Morgan Healthcare Conference presentation

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Jan 7, 2026, 7:00 AM EST - 8 months ago

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

Biohaven's depression drug fails mid-stage trial, shares fall

Dec 24, 2025, 3:24 PM EST - 8 months ago

Biohaven's depression drug fails mid-stage trial, shares fall

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Dec 24, 2025, 1:00 PM EST - 8 months ago

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Dec 11, 2025, 7:00 AM EST - 9 months ago

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Nov 13, 2025, 4:05 PM EST - 10 months ago

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Nov 12, 2025, 7:15 AM EST - 10 months ago

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares

Nov 11, 2025, 4:05 PM EST - 10 months ago

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Biohaven Quarterly report: Q3 2025

Biohaven Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Biohaven Earnings release: Q3 2025

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Nov 10, 2025, 6:58 AM EST - 10 months ago

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Biohaven shares plunge after US FDA declines to approve brain disorder drug

Nov 5, 2025, 10:02 AM EST - 10 months ago

Biohaven shares plunge after US FDA declines to approve brain disorder drug

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Nov 4, 2025, 8:06 PM EST - 10 months ago

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Biohaven Slides: Corporate Presentation

Aug 12, 2025, 8:00 PM EDT - 1 year ago

Biohaven Slides: Corporate Presentation

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Biohaven Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Biohaven Quarterly report: Q2 2025

Biohaven Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Biohaven Earnings release: Q2 2025

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Jul 18, 2025, 12:06 PM EDT - 1 year ago

Law Offices of Frank R. Cruz Encourages Biohaven Ltd.

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Jul 18, 2025, 12:00 PM EDT - 1 year ago

Law Offices of Howard G. Smith Encourages Biohaven Ltd.

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

Jul 15, 2025, 10:46 AM EDT - 1 year ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. (BHVN)

MakerQuants
MakerQuants Sep. 9 at 4:05 PM
$BHVN 😲
0 · Reply
anachartanalyst
anachartanalyst Sep. 8 at 6:02 PM
$BHVN https://anachart.com/wp-content/uploads/2026/09/1788890498_soc-img.jpg
0 · Reply
Timefortendies77
Timefortendies77 Sep. 8 at 1:59 PM
$BHVN Someone wanted to buy more.
0 · Reply
Timefortendies77
Timefortendies77 Sep. 8 at 1:31 PM
$BHVN Wow ok 5% down, looks like shorties came to play today.
0 · Reply
Timefortendies77
Timefortendies77 Sep. 7 at 3:44 PM
$BHVN The Path to Becoming the New King-------Efficacy: Prior data on taldefgrobep (from its original testing in spinal muscular atrophy) showed it could drive over a 6% reduction in fat mass while simultaneously increasing lean muscle mass. If those numbers translate cleanly to an obesity cohort as a standalone treatment, it proves the mechanism is an absolute powerhouse. The Side Effect Advantage: The real crown will be won on tolerability. Lilly's bimagrumab has faced hurdles with severe muscle spasms and diarrhea because it binds rigidly to the receptor. If Biohaven’s "ligand trap" approach successfully cleans up the target proteins before they hit the receptor—yielding great body composition with a clean safety profile—it removes the single biggest barrier to widespread adoption.
0 · Reply
Timefortendies77
Timefortendies77 Sep. 7 at 3:13 PM
$BHVN Success in Obesity could be game changing for Biohaven and make the pop for the Epilepsy KV7 drug sale look like pennies compared to what the stock could do here. No Analyst is pricing it in success with obesity----they do not want to be wrong. That means anything that happens is NOT priced in. If it doesn't hit the stock will def take a hit--maybe back down to the 10-12 zone (but of course not to the ground as there are many assets here). It seems the Analysts talk the most about Degraders as they are going into P3 and are more proven than Obesity. Summary-Obesity is a total wild card.
0 · Reply
Timefortendies77
Timefortendies77 Sep. 3 at 9:46 PM
$BHVN Obesity=October
0 · Reply
MonkeyBananaGenius
MonkeyBananaGenius Sep. 3 at 12:33 PM
$BHVN very interesting back story on this one. Precommercial but robust pipeline. Chart looks constructive.
1 · Reply
Valueforall
Valueforall Sep. 2 at 6:33 PM
$BHVN I went against my rule and went 2.5x overweight in dis muddhphukka!
0 · Reply
Dheeraj_6
Dheeraj_6 Sep. 2 at 2:27 PM
$BHVN MM trying hard to manipulate the SP,from +6% on opening to -1% in an hour on such a low volume. I am hopeful we hit Obesity this year, with that this will soar to minimum to $25.
0 · Reply
Valueforall
Valueforall Sep. 2 at 2:22 PM
$BHVN Nevermind. Bought 15.54
1 · Reply
Valueforall
Valueforall Sep. 2 at 2:04 PM
$BHVN bought 15.62. Last buy today!
0 · Reply
Valueforall
Valueforall Sep. 2 at 1:56 PM
$BHVN bought 15.68
0 · Reply
Valueforall
Valueforall Sep. 2 at 1:50 PM
$BHVN loaded big right here
0 · Reply
Valueforall
Valueforall Sep. 2 at 1:48 PM
$BHVN adding
0 · Reply
KirRoyalTrader
KirRoyalTrader Sep. 1 at 7:57 PM
$BHVN Biohaven bouncing from a nice confluence zone: the June 17 AVWAP + rising 21 DMA structure, following the pullback from its explosive August 26 move.
0 · Reply
TI7812
TI7812 Sep. 1 at 7:39 PM
$BHVN $KURA $RVMD $ABCL a few of the many biotechs up on my screens today. like money is rotating into them - well at least its not leaving. Interest rates have zero impact on their futures. so keep playing the game.
0 · Reply
Timefortendies77
Timefortendies77 Sep. 1 at 1:51 PM
$BHVN I think we all know this is going to moon if the Obesity drug hits based on the record of what has happened with Myostatin drugs that succeed in trials? (such as Scholar Rock). If it doesn't NO analyst seems to be counting it in --all they talk about now is Degraders so I can't see this moving lower than 12 on bad obesity news --given all the cash we have now. We then just become a degrader stock? Thoughts? What are your PT if Obesity hits or doesn't?
0 · Reply
Stanman13
Stanman13 Sep. 1 at 12:36 AM
$BHVN Pre Market looks 🔥
1 · Reply
Spincognito
Spincognito Aug. 31 at 4:18 PM
$BHVN anyone see the news regarding Lilly’s acquisition of Merida Biosciences? For those not familiar their lead asset is early stage for Graves’ disease. I would have expected Biohaven’s stock to have been up on the news.
2 · Reply
FactsPlease99
FactsPlease99 Aug. 31 at 12:36 PM
$XENE $BHVN $PRAX its gonna be battle with a crowded market with XENE, Biohaven, SK, and also Longboard! Doctors will be so bombarded and overwhelmed on Focal seizure treatments...basicaly all good seizure outcomes... Xenon and bio haven no titration is a big advantage and seizure freedom LT seems good for both. Xenon the soonest approval...Oh now let's throw in Praxis for some more fun!! dammmmm thats a lot of choices. 5 new drugs for Focal....
0 · Reply
net0trader
net0trader Aug. 31 at 12:48 AM
Blog post for this week is now ready. Don't miss the macro read: https://net0trader.substack.com/p/the-week-of-august-24-a-108-billion?r=8cs7pu&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true $RVMD $BHVN $VERA $NVDA $CVX
0 · Reply